Ilaris

This page shows the latest Ilaris news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: EULAR kicks off in Amsterdam, May brings together remainers and brexiteers and Autolus launches its IPOS

On today’s agenda expect new trial data from Novartis' Ilaris in gout, Lilly's Oluminant in systemic lupus and AbbVie's new JAK inhibitor upadacitinib.

Latest news

CV data sets up Novartis' Ilaris for blockbuster sales

CV data sets up Novartis' Ilaris for blockbuster sales. Drug shown to reduce major adverse cardiovascular events. ... Novartis has posted surprise phase III data that could transform the fortunes of its anti-inflammatory drug Ilaris, making it an option
Novartis' Ilaris wins three new FDA approvals

Novartis' Ilaris wins three new FDA approvals. Immunotherapeutic expands in rare Periodic Fever Syndrome conditions. ... Novartis' anti-inflammatory therapy Ilaris (canakinumab) has received new US approvals for its use in three rare Periodic Fever
Novartis wins childhood arthritis indication for Ilaris in EU

Novartis wins childhood arthritis indication for Ilaris in EU. EC gives green light to drug for the treatment of systemic juvenile idiopathic arthritis. ... Novartis' inflammatory disease drug Ilaris (canakinumab) can be used more widely in the EU
Novartis lifts 2013 guidance on delay to Diovan generics

Jimenez also said Novartis had a fertile quarter in terms of its pipeline, with four approvals including Ilaris (canakinumab) for systemic juvenile idiopathic arthritis, Simbrinza (brinzolamide/brimonidine tartrate) for glaucoma, Lucentis
Novartis gets FDA green light for new Ilaris indication

Novartis gets FDA green light for new Ilaris indication. Immunotherapeutic wins US approval for severe form of childhood arthritis. ... The new SJIA indication will add further momentum to Ilaris, which grew 56 per cent last year to reach $72m in sales.

More from news
Approximately 4 fully matching, plus 7 partially matching documents found.

Latest appointments

AIMM Therapeutics appoints former Novartis VP Jan de Vries as CEO

During his time at Novartis, de Vries led the discovery and early development of several drugs including Elidel (pimecrolimus) for eczema, Ilaris (canakunimab) for cryopyrin-associated periodic syndromes, Gilenya (fingolimod) for

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Home based, Senior Medical Writer, Medical Communications: Excellent package

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Delivery Manager/ Head of Delivery – Executive Search: Neg

Home based, Chief Medical Writer, Medical Communications: Excellent package

Healthcare PR Director: £100, 000 – £120, 000 benefits

Editorial Director – Medical Education (MedComms): Neg

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Editorial Team Leader, Medical Communications: Excellent package

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Client Services Director - Med Comms: Great salary and bebefits

Home based, Principal Medical Writer, Medical Communications: Excellent package

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Senior Account Manager: Competitive salary commensurate with experience

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Client Services Director – Healthcare Advertising - London: Neg

Account Manager: £40, 000 - £45, 000 benefits

Business Unit Head, Medical Communications, London: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....